We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Open Orphan Plc | LSE:ORPH | London | Ordinary Share | GB00B9275X97 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 10.00 | 9.50 | 10.50 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
16/11/2020 10:33 | From somebody who confessed to not having heard him speak for a few months (!) it is interesting that you are criticising him about the last one. I had no problem with it. The sound could have been better but I am here for the gain to be made on the share price not the acoustics.Seen a few shares where after great gains some people turn against the CEO or BOD. Would be crazy for that to happen here. | inaminute | |
16/11/2020 10:31 | Should be interesting when Q4 results are announced | malcolmmm | |
16/11/2020 10:27 | Busy board here this morning. It's amazing the amount of people complaining when the share price drops a little. | ross k | |
16/11/2020 10:22 | judijudi, This opened on Friday morning at 24-25.5p, surely you accept some of the froth on Friday was due to the interview that night and the UT price of 26.5p giving us a high close, the froth has sold off this morning but we are still in a better place than we were Friday opening. | troutisout | |
16/11/2020 10:18 | Plasybryn I dont recognize any of your critical points on CFs presentations. I have only ever had clarity of sound, he speaks well and the slides are a standard set he uses to introduce the company to people who have never heard of it we only get the new stuff at the end. | pogue | |
16/11/2020 10:18 | beep beep beep, hey guess what, i cant finish a sentence to save me life, beep beep beep, my watch is telling me you've all been conned, lol nasdaq is for listing businesses not an unfinished product, no wonder it's all delayed, beep beep beep, lol and, no one has bought the beep beep beeping bloody vaccine cause it's probably a dud. | homeboy | |
16/11/2020 10:15 | Aye Malc, Fridays interview has done wonders for the share price this morning | judijudi | |
16/11/2020 10:10 | He knows that the more he talks about his great company and his ambitions on the media the more it will help the sp | malcolmmm | |
16/11/2020 10:08 | I've never known a Co. present so often. He must love it. What is the reason? I hope he takes on board some of the feedback about poor sound (echo) and clarity of diction. Finishing sentences. Speaking slower and improving the slides to make them more impactful. Less words. Less is more. | plasybryn | |
16/11/2020 10:08 | Fees are higher on Nasdag but it opens up the company to a vastly bigger market, the shares would double and then some imo. A wearable contract or two would be nice and may happen at any time in which case a nasdag listing would be assential imo,also there are a few health companies that they could merge with imo | malcolmmm | |
16/11/2020 10:05 | Why is he presenting again 🤷a Never thought I would ever ask that about a ceo who’s company I have shares in 😀 | judijudi | |
16/11/2020 10:00 | troutisout CF seemed to be to be talking more about a NASDAQ float than a sale in the last presentation subtle change in how he has been talking from earlier presentations. Cost wise I don't see it being millions to reverse into an existing NASDAQ company which appears to be the route to listing we will be taking. | pogue | |
16/11/2020 09:59 | He is presenting next Thursday, so don't be shy to ask more challenging questions. This halo effect is a bit silly at times. It is dangerous for him to think investors will always make out he is invincible. | plasybryn | |
16/11/2020 09:57 | m5 Fine by me, I learnt years ago not to take everything said by a Chairman or CEO as a promise, no matter how excited I was getting.... | troutisout | |
16/11/2020 09:53 | troutisout16 Nov '20 - 09:43 - 8173 of 8174 I have listened to every presentation, I know what was said and how it was said. That's enough on the subject. | m5 | |
16/11/2020 09:53 | pogue, You say no obvious buyer so going to the Nasdaq. First we don't know what is happening with potential buyers, a Nasdaq listing would take lot of time and cost many, many millions. So what happens when a competitor's vaccine misses stage 3 objectives drops hugely in value and is listed on Nasdaq??? Surely it has to be looked at... | troutisout | |
16/11/2020 09:53 | CFs presentations recently told us about expanding out of the UK and wearables, he cant have a show stopper every time having presentations lined up gives him ability to pass news on as it happens it certainly has been exciting last few weeks even if the share price seems to be lagging the news. Anyway it gives us a chance to ask him questions at the end and try and dig out some clarity. | pogue | |
16/11/2020 09:45 | m5, CF has delivered on the majority No doubt about it However there is no point holding a presentation to basically announce a delay in selling a major asset (why the delay. Is nobody interested?) and a delay in a divi payment and then a re hash of much of the last presentation Better for CF to keep quiet and get on with the jobs in hand and stop trying to hog the camera imho Saying that I wish TK would take a leaf out of CF’s book on “company promotion” That’s my lot on the subject for now also | judijudi | |
16/11/2020 09:43 | m5 Thanks, so it was an option not that there would be one. So just like anything people need to listen to what was said and not what they want to hear.... | troutisout | |
16/11/2020 09:42 | Looks like the BBC has finally worked out the world has not been saved by Pfizer... ....However, many types of vaccine are likely to be needed to end the pandemic. The success of the vaccine developed by Pfizer and BioNTech has caused global excitement. However, it has not yet been approved for use and we still do not know how well it works in the elderly or how long immunity lasts. The hunt for Covid vaccines continues as a different approach may yet be better, or better in some age groups, and one company will struggle to immunise the planet. How close are we to a coronavirus vaccine? Who will get the vaccine first and when can you have it? "It is really important we pursue many different vaccines from many different manufactures," said Prof Saul Faust, the director of the NIHR Southampton Clinical Research Facility, who will run the trial.... | pogue | |
16/11/2020 09:39 | Can see how we are going down on a delay for the sale of imutex its not even in the share price in fact not even the challenge studies are fully in the price. There is no obvious buyer coming forward for imutex it would appear so going to the NASDAQ. Perhaps listing just before Xmas is not good timing for that who knows all will come to those that wait. | pogue | |
16/11/2020 09:35 | troutisout16 Nov '20 - 09:18 - 8167 of 8170 He set the expectation up that is was a distinct possibility either from Imutex sale OR from the cash pile which would be substantially more by then. Anyway I have said my bit on this, I felt disappointed and I know I was not alone and not talking traders but long termers. When I heard it I expected weakness in the share price on Monday. Lets move on now. Judi, you recent post about delivery. No one in their right mind can think that CF has not delivered. The performance of this business and the share price within a relatively short period is staggering. Come on as an EME shareholder you should know about non delivery!! I still have a few myself. | m5 | |
16/11/2020 09:29 | Delayed trades going through from earlier.... | troutisout |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions